ARBACLOFEN PLACARBIL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H26ClNO6
Molecular Weight	399.866
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C

InChI

InChIKey=JXTAALBWJQJLGN-KSSFIOAISA-N

InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H26ClNO6
Molecular Weight	399.866
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27748740 | https://www.ncbi.nlm.nih.gov/pubmed/28616094 | https://clinicaltrials.gov/ct2/show/NCT01743651

Arbaclofen (STX209, R-baclofen), a selective agonist of GABA-B receptors, has been investigated in clinical trials for the treatment of autism spectrum disorder ASD, phase II and for the treatment of patients with fragile X syndrome in phase III. As a result, the drug did not meet the primary outcome of improved social avoidance in FXS in either study. In spite of positive results in some children with ASD, further study will be needed to replicate and extend these initial findings. Arbaclofen has also been investigated in phase III clinical trials as a treatment for spasticity due to multiple sclerosis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-B receptor 32 Target ID: CHEMBL2111463 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22993295	Agonist 2752

PubMed

Title	Date	PubMed
Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors.	1997 Mar 20	9069281
Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.	2012 Sep 19	22993295
Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder.	2014	24872724

Patents

Sample Use Guides

In Vivo Use Guide

5 mg BID to 15 mg TID

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:03:27 GMT 2025` Edited by `admin` on `Wed Apr 02 09:03:27 GMT 2025`
Record UNII	W89H91R7VX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

XP-19986

Preferred Name

English

ARBACLOFEN PLACARBIL

Official Name

English

BENZENEPROPANOIC ACID, 4-CHLORO-.BETA.-(((((1S)-2-METHYL-1-(2-METHYL-OXOPROPOXY)PROPOXY)CARBONYL)AMINO)METHYL)-, (.BETA.R)-

Common Name

English

(3R)-3-(4-Chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid

Systematic Name

English

arbaclofen placarbil [INN]

Common Name

English

ARBACLOFEN PLACARBIL [USAN]

Common Name

English

XP19986

Code

English

ARBACLOFEN PLACARBIL [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2199